An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
This study is testing a medication called inebilizumab in children and teenagers with neuromyelitis optica spectrum disorder, a rare condition affecting the central nervous system. Researchers want to see how the medication behaves in younger bodies, how safe it is, and how well it helps control the disease.
Children and teenagers aged 2 to under 18 who weigh at least 33 pounds and have a confirmed diagnosis of the condition with specific antibodies in their blood may join. Participants must also have a history of recent flare-ups and meet overall health requirements set by the study doctors.
Participants will receive the study medication, inebilizumab, which targets specific immune cells involved in the condition. The medical team will closely monitor their health, safety, and how the drug affects their body through regular check-ups and lab tests.
This study is currently recruiting participants at locations in California and Massachusetts within the United States. You can talk to your doctor or the study team to find the most convenient location and learn more about getting involved.
- 1Testing the safety and effects of inebilizumab in pediatric patients
- 2Open to children and teens aged 2 to 17 with specific antibodies
- 3Currently recruiting patients at select medical centers in the US
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.